Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating monotherapy HL1113R1 or HL1113R2 versus fixed-dose combination in essential hypertension with type 2 diabetes; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension
• Type 2 Diabetes Mellitus

Drugs mentioned

• HL1113
• HL1113R1
• HL1113R2

Snippet

Sponsor: Hanlim Pharm. Co., Ltd. | Conditions: Hypertension, Diabete Type 2 | Phase 3 | Status: RECRUITING